No licensed hantavirus vaccine exists for New World strains such as Andes or Sin Nombre viruses responsible for most U.S. and Latin American cases, with all candidates remaining in preclinical or early Phase 1 stages as of September 2026. mRNA platforms from Moderna-Korea University and UTMB have shown strong protection in rodent models, including single-dose efficacy against Andes virus, while older DNA vaccines targeting Hantaan/Puumala have completed small Phase 1 safety and immunogenicity trials but lack Phase 3 efficacy data. Low disease incidence complicates large-scale human testing, and recent outbreaks like the MV Hondius cluster have boosted research interest without shifting regulatory timelines. Trader consensus reflects the multi-year requirements for Phase 2/3 trials, manufacturing scale-up, and approvals, though accelerated funding or emergency authorization after a major event could theoretically compress the schedule.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
5% সম্ভাবনা
$135,595 Vol.
$135,595 Vol.
Dec 31, 2026
5% সম্ভাবনা
$135,595 Vol.
$135,595 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine exists for New World strains such as Andes or Sin Nombre viruses responsible for most U.S. and Latin American cases, with all candidates remaining in preclinical or early Phase 1 stages as of September 2026. mRNA platforms from Moderna-Korea University and UTMB have shown strong protection in rodent models, including single-dose efficacy against Andes virus, while older DNA vaccines targeting Hantaan/Puumala have completed small Phase 1 safety and immunogenicity trials but lack Phase 3 efficacy data. Low disease incidence complicates large-scale human testing, and recent outbreaks like the MV Hondius cluster have boosted research interest without shifting regulatory timelines. Trader consensus reflects the multi-year requirements for Phase 2/3 trials, manufacturing scale-up, and approvals, though accelerated funding or emergency authorization after a major event could theoretically compress the schedule.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
মার্কেট ওপেন হয়েছে: May 4, 2026, 10:39 AM ET
ভলিউম
$135,595শেষ তারিখ
Jan 1, 2027মার্কেট ওপেন হয়েছে
May 4, 2026, 10:39 AM ETরেজলভার
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine exists for New World strains such as Andes or Sin Nombre viruses responsible for most U.S. and Latin American cases, with all candidates remaining in preclinical or early Phase 1 stages as of September 2026. mRNA platforms from Moderna-Korea University and UTMB have shown strong protection in rodent models, including single-dose efficacy against Andes virus, while older DNA vaccines targeting Hantaan/Puumala have completed small Phase 1 safety and immunogenicity trials but lack Phase 3 efficacy data. Low disease incidence complicates large-scale human testing, and recent outbreaks like the MV Hondius cluster have boosted research interest without shifting regulatory timelines. Trader consensus reflects the multi-year requirements for Phase 2/3 trials, manufacturing scale-up, and approvals, though accelerated funding or emergency authorization after a major event could theoretically compress the schedule.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
ভলিউম
$135,595শেষ তারিখ
Jan 1, 2027মার্কেট ওপেন হয়েছে
May 4, 2026, 10:39 AM ETরেজলভার
0x65070BE91...No licensed hantavirus vaccine exists for New World strains such as Andes or Sin Nombre viruses responsible for most U.S. and Latin American cases, with all candidates remaining in preclinical or early Phase 1 stages as of September 2026. mRNA platforms from Moderna-Korea University and UTMB have shown strong protection in rodent models, including single-dose efficacy against Andes virus, while older DNA vaccines targeting Hantaan/Puumala have completed small Phase 1 safety and immunogenicity trials but lack Phase 3 efficacy data. Low disease incidence complicates large-scale human testing, and recent outbreaks like the MV Hondius cluster have boosted research interest without shifting regulatory timelines. Trader consensus reflects the multi-year requirements for Phase 2/3 trials, manufacturing scale-up, and approvals, though accelerated funding or emergency authorization after a major event could theoretically compress the schedule.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা